Menu
← Oncology Approval Tracker
FDA DECISION ·
Akeega + prednisone
niraparib + abiraterone acetate + prednisone · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with metastatic castration-resistant prostate cancer with a deleterious or suspected deleterious BRCA alteration on an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
A fixed-dose PARP inhibitor and androgen-synthesis inhibitor combination addressed a BRCA-selected population.
What research teams should watch
Confirm the specific BRCA result and monitor the hematologic and endocrine requirements of the combined regimen.
PRIMARY RECORDS